The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Target Recruit Count
- 53
- Registration Number
- NCT05431504
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy
- Conditions
- Patients With Advanced Solid Tumors
- Interventions
- Biological: human single chain IL-12 mRNA-single doseBiological: human single chain IL-12 mRNA-multiple dose
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-06-22
- Target Recruit Count
- 60
- Registration Number
- NCT05392699
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma
- Conditions
- Metastatic Nasopharyngeal Cancer
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-02-05
- Target Recruit Count
- 34
- Registration Number
- NCT05385926
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
- Conditions
- Early-stage Breast Cancer
- Interventions
- Other: The MRD strategy for high risk or MRD+ TNBC patientsOther: The MRD strategy for high risk or MRD+ ER+ patientsOther: The MRD strategy for low risk and MRD- ER+ patientsOther: The MRD strategy for high risk or MRD+ HER2+ patientsOther: The MRD strategy for low risk and MRD- TNBC patientsOther: The MRD strategy for low risk and MRD- HER2+ patients
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Target Recruit Count
- 300
- Registration Number
- NCT05345860
- Locations
- 🇨🇳
Beijing Huanxing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Center, Langfang, Hebei, China
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-04-15
- Target Recruit Count
- 64
- Registration Number
- NCT05331326
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Huanxing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Center, Langfang, Hebei, China
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
- Conditions
- Cervical Esophageal Cancer
- Interventions
- Procedure: Esophagectomy
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Target Recruit Count
- 192
- Registration Number
- NCT05327517
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105
- Conditions
- Hand and Foot Skin ReactionColorectal Cancer Stage IV
- Interventions
- Drug: Traditional chinese medicine TDX105Drug: Placebo
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2022-03-21
- Target Recruit Count
- 152
- Registration Number
- NCT05289726
- Locations
- 🇨🇳
Cancer hospital Chinese academy of Medical sciences, Beijing, Beijing, China
Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-03-19
- Target Recruit Count
- 122
- Registration Number
- NCT05283616
- Locations
- 🇨🇳
Department of Medical Oncology, Beijing, Beijing, China
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
- Conditions
- Mesothelioma, MalignantMesothelioma, Malignant PleuralMesothelioma Malignant Advanced
- Interventions
- Drug: Sintilimab+Anlotinib+Pemetrexed+Cisplatin
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 29
- Registration Number
- NCT05188859
- Locations
- 🇨🇳
Shanxi Provincial Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer
- Conditions
- Cervical Cancer Stage IB1
- Interventions
- Procedure: Carbon nanoparticlesProcedure: Indocyanine green
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2021-12-22
- Target Recruit Count
- 144
- Registration Number
- NCT05167149
- Locations
- 🇨🇳
Department of Gynecological Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China